Alaunos Therapeutics Inc TCRT Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$1.74 down $0.10, 5.43% at close Nov 6
Last close · Previous close $1.84
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.91Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$1.74up $1.00, 134.35%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$1.84Nov 5
- Volume101.46KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume19.96MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.72 to $4.50; now $1.74
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
TCRT beat the S&P 500 in 1 of 7 periods.
| Period | TCRT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | TCRT: up 134.4% S&P 500: down 5.6% | TCRT beat the S&P 500 by 140.0 percentage points Beat |
| 3M | TCRT: down 12.6% S&P 500: down 4.1% | TCRT trailed the S&P 500 by 8.5 percentage points Trailed |
| YTD | TCRT: down 46.1% S&P 500: up 8.7% | TCRT trailed the S&P 500 by 54.8 percentage points Trailed |
| 1Y | TCRT: down 29.3% S&P 500: up 10.9% | TCRT trailed the S&P 500 by 40.2 percentage points Trailed |
| Long term | ||
| 3Y | TCRT: down 86.6% S&P 500: up 75.0% −48.9% vs +20.5% a year | TCRT trailed the S&P 500 by 161.6 percentage points Trailed |
| 5Y | TCRT: down 99.3% S&P 500: up 67.8% −62.8% vs +10.9% a year | TCRT trailed the S&P 500 by 167.1 percentage points Trailed |
| 10Y | TCRT: down 99.8% S&P 500: up 313.1% −46.0% vs +15.2% a year | TCRT trailed the S&P 500 by 412.9 percentage points Trailed |
$10,000 invested in TCRT 10 years ago (Nov 4, 2016) would be worth about $21 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
TCRT beat the S&P 500 in 1 of 7 periods.
| Period | TCRT and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | TCRT: up 134.4% S&P 500: down 5.6% | TCRT beat the S&P 500 by 140.0 percentage points Beat |
| 3M | TCRT: down 12.6% S&P 500: down 4.3% | TCRT trailed the S&P 500 by 8.3 percentage points Trailed |
| YTD | TCRT: down 46.1% S&P 500: up 7.8% | TCRT trailed the S&P 500 by 53.9 percentage points Trailed |
| 1Y | TCRT: down 29.3% S&P 500: up 9.7% | TCRT trailed the S&P 500 by 39.0 percentage points Trailed |
| Long term | ||
| 3Y | TCRT: down 86.6% S&P 500: up 68.8% −48.9% vs +19.1% a year | TCRT trailed the S&P 500 by 155.4 percentage points Trailed |
| 5Y | TCRT: down 99.3% S&P 500: up 56.9% −62.8% vs +9.4% a year | TCRT trailed the S&P 500 by 156.2 percentage points Trailed |
| 10Y | TCRT: down 99.8% S&P 500: up 252.6% −46.0% vs +13.4% a year | TCRT trailed the S&P 500 by 352.4 percentage points Trailed |
$10,000 invested in TCRT 10 years ago (Nov 4, 2016) would be worth about $21 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$96,000.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Aug 24, 2005.
Stock splits
3
Latest: 1-for-10 on . Share counts adjust after each split.
All 3 splits
- 1-for-10
- 1-for-15
- 1-for-40
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $3.00Kdown 25.0%
- Net income
- −$4.01M
- Diluted EPS
- −$1.91
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$1.13M | −$0.70 |
| Q4 FY24 (Dec 31, 2024) | $4.00K | −$742.00K | −$0.46 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$1.07M | −$0.67 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$1.05M | −$0.63 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$1.16M | −$0.55 |
| Q4 FY25 (Dec 31, 2025) | $3.00K | −$893.00K | −$0.36 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$1.01M | −$0.59 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$952.00K | −$0.41 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $398.00K | −$78.75M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $2.92M | −$37.73M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $5.00K | −$35.14M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $10.00K | −$4.68M | −$2.92 |
| FY25 (Dec 31, 2025) | $5.00K | −$4.18M | −$2.20 |
Margins
- Gross 100.0%
- Operating −135,266.7%
- Net −133,666.7%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$2.73MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$2.73MLast 12 months
- Capital spending$1.00KLast 12 months
- −90,933.3%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $0.00Last 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $124.00KAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$0.00As of Jun 30, 2026
- Net cash$124.00KAs of Jun 30, 2026
- 0.77As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.00As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −232.6%Last 12 months
Over the last 12 months, Alaunos Therapeutics lost money: its net loss was 232.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −159.0%Last 12 months
Over the last 12 months, Alaunos Therapeutics’s net loss was 159.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Alaunos Therapeutics Inc
Alaunos Therapeutics is a T-cell receptor (TCR) cell therapy company powered by its hunTR® (human neoantigen T-cell Receptor) discovery platform. hunTR® enables the rapid identification of wholly owned, proprietary TCRs. Using a proprietary high-throughput TCR screening process, hunTR® enables rapid functional validation of TCRs potentially allowing Alaunos to advance new TCRs from the lab to testing in the clinic.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
TCRT news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
TCRT stock FAQ
What is TCRT stock’s price today?
Alaunos Therapeutics (TCRT) traded at $1.74 at the close on , down $0.10 (5.43%) from the previous close of $1.84. Over the past 52 weeks it has traded between $0.72 and $4.50.
If you invested $1,000 in TCRT 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in TCRT on would be worth about $2 at the close on , a total return of −99.8%. The same $1,000 would be worth $7 if invested five years ago, $707 if invested one year ago, and $2 if invested 20 years ago. Past performance doesn’t predict future returns.
What is TCRT’s P/E ratio?
TCRT’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.91).
How much revenue does Alaunos Therapeutics make?
Alaunos Therapeutics reported $3.0 thousand of revenue over the four quarters to , down 25.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $0.0 thousand.
Is Alaunos Therapeutics profitable?
Not over the four quarters to . Alaunos Therapeutics reported a net loss of $4.0 million across those four quarters on $3.0 thousand of revenue.
What are TCRT’s earnings per share?
TCRT’s diluted earnings per share were −$1.91 over the four quarters to , compared with −$2.46 in the twelve months before. The latest quarter (Q2 FY26) brought −$0.41 per share, against −$0.63 a year earlier (how EPS works).
Does TCRT pay a dividend?
Alaunos Therapeutics hasn’t paid a dividend in the last twelve months.
What is TCRT’s 52-week high and low?
Over the past 52 weeks TCRT has traded as low as $0.72 and as high as $4.50. At $1.74 at the close on , it is 61.3% below that high and 142.0% above the low.
What is TCRT’s all-time high?
TCRT’s highest closing price was $96,000.00 on , adjusted for stock splits. At $1.74 at the close on , it is 100.0% below that record.
Has TCRT stock ever split?
Yes, three times: 1-for-40 on ; 1-for-15 on ; 1-for-10 on .
How has TCRT stock performed?
Including dividends and measured to the close on , TCRT has returned −46.1% so far this year and −29.3% over the past year, and −99.3% over five years (−62.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Alaunos Therapeutics in?
Alaunos Therapeutics is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does TCRT trade on?
Alaunos Therapeutics trades on the Nasdaq under the ticker symbol TCRT. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.